Αποτελέσματα αναζήτησης - Su‐Peng Yeh

Περιορισμός αποτελεσμάτων
  1. 1
    Myocyte Enhancer Factor-2 Interacting Transcriptional Repressor (MITR) Is a Switch That Promotes Osteogenesis and Inhibits Adipogenesis of Mesenchymal Stem Cells by Inactivating Peroxisome Proliferator-activated Receptor γ-2

    Myocyte Enhancer Factor-2 Interacting Transcriptional Repressor (MITR) Is a Switch That Promotes Osteogenesis and Inhibits Adipogenesis of Mesenchymal Stem Cells by Inactivating Pe... από Ya-Huey Chen, Fang-Ling Yeh, Su-Peng Yeh, Haou-Tzong Ma, Shih‐Chieh Hung, Mien‐Chie Hung, Long‐Yuan Li

    Έκδοση 2011
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  2. 2
    Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study

    Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study από Ming-Yu Lien, Chia-Hui Chou, Ching‐Chan Lin, Li‐Yuan Bai, Chang‐Fang Chiu, Su‐Peng Yeh, Mao-Wang Ho

    Έκδοση 2018
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  3. 3
    Enhancer of Zeste Homolog 2 and Histone Deacetylase 9c Regulate Age-Dependent Mesenchymal Stem Cell Differentiation into Osteoblasts and Adipocytes

    Enhancer of Zeste Homolog 2 and Histone Deacetylase 9c Regulate Age-Dependent Mesenchymal Stem Cell Differentiation into Osteoblasts and Adipocytes από Ya-Huey Chen, Chiao-Chen Chung, Yu-Chia Liu, Su-Peng Yeh, Jennifer L. Hsu, Mien‐Chie Hung, Hong-Lin Su, Long‐Yuan Li

    Έκδοση 2016
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  4. 4
    The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells

    The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells από Jing-Yi Chen, You-Syuan Lai, Hui‐Jen Tsai, Cheng-Chin Kuo, B. Linju Yen, Su-Peng Yeh, H. Sunny Sun, Wen-Chun Hung

    Έκδοση 2016
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  5. 5
    Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection—A Double Blind, Multi-Center, Randomized Phase IV Study

    Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection—A Double Blind, Multi-Center, Randomized Ph... από Cheng‐Hsu Wang, Cheng-Yao Lin, Jen‐Shi Chen, Ching-Liang Ho, Kun-Ming Rau, Jo-Ting Tsai, Cheng-Shyong Chang, Su-Peng Yeh, Chieh-Fang Cheng, Yuen‐Liang Lai

    Έκδοση 2019
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  6. 6
    CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells

    CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells από Yongkun Wei, Ya-Huey Chen, Long‐Yuan Li, Jing‐Yu Lang, Su-Peng Yeh, Bin Shi, Cheng‐Chieh Yang, Jer-Yen Yang, Chun-Yi Lin, Chien‐Chen Lai, Mien‐Chie Hung

    Έκδοση 2010
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  7. 7
    EZH2 Regulates Neuronal Differentiation of Mesenchymal Stem Cells through PIP5K1C-dependent Calcium Signaling

    EZH2 Regulates Neuronal Differentiation of Mesenchymal Stem Cells through PIP5K1C-dependent Calcium Signaling από Yung‐Luen Yu, Ruey‐Hwang Chou, Ling-Tzu Chen, Woei‐Cherng Shyu, Su-Ching Hsieh, Chen‐Shiou Wu, Hong-Jie Zeng, Su-Peng Yeh, De‐Ming Yang, Shih‐Chieh Hung, Mien‐Chie Hung

    Έκδοση 2011
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  8. 8
    P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE

    P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACE... από Hartmut Döhner, Pau Montesinos, Susana Vives Polo, Ewa Zarzycka, Jianxiang Wang, Marta Riva, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Jianan Hui, Diego A. Gianolio, Prapti A. Patel, Christian Récher, Stéphane de Botton

    Έκδοση 2023
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  9. 9
    Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia

    Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia από Pau Montesinos, Christian Récher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Giambattista Bertani, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Scott R. Daigle, Jianan Hui, Shuchi S. Pandya, Diego A. Gianolio, Stéphane de Botton, Hartmut Döhner

    Έκδοση 2022
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  10. 10
    AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an <i>IDH1</i> Mutation

    AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an <i... από Pau Montesinos, Christian Récher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Giambattista Bertani, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Scott R. Daigle, Jianan Hui, Vickie Zhang, Shuchi S. Pandya, Diego A. Gianolio, Stéphane de Botton, Hartmut Döhner

    Έκδοση 2021
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  11. 11
    Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

    Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy από Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Jun‐Ho Jang, Su‐Peng Yeh, Grace Ku, Ying Zhou, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

    Έκδοση 2022
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  12. 12
    A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

    A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients από Hui‐Jen Tsai, Shih Sheng Jiang, Wen-Chun Hung, Gautam Borthakur, Sheng-Fung Lin, Naveen Pemmaraju, Elias Jabbour, John S. Bomalaski, Yaping Chen, Hui-Hua Hsiao, Ming-Chung Wang, Ching-Yuan Kuo, Hung Chang, Su-Peng Yeh, Jorge E. Cortés, Li‐Tzong Chen, Tsai‐Yun Chen

    Έκδοση 2017
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  13. 13
    Smurf2‐mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke

    Smurf2‐mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke από Yung‐Luen Yu, Ruey‐Hwang Chou, Woei‐Cherng Shyu, Shu‐Ching Hsieh, Chen‐Shiou Wu, Shu‐Ya Chiang, Wei‐Jung Chang, Jia‐Ni Chen, Yen‐Ju Tseng, Yu‐Hsuan Lin, Wei Lee, Su‐Peng Yeh, Jennifer L. Hsu, Cheng‐Chieh Yang, Shih‐Chieh Hung, Mien‐Chie Hung

    Έκδοση 2013
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  14. 14
    Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

    Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine από Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Christian Récher, Andre C. Schuh, Michael J. Thirman, Jacqueline S. Garcia, Courtney D. DiNardo, Vladimir Vorobyev, Nicola Fracchiolla, Su‐Peng Yeh, Jun Ho Jang, Muhi̇t Özcan, Kazuhito Yamamoto, Árpád Illés, Ying Zhou, Monique Dail, Brenda Chyla, Jalaja Potluri, Hartmut Döhner

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  15. 15
    Molecular Characterization of Clinical Response and Relapse in Patients with <i>IDH1</i>m ND-AML Treated with Ivo+AZA in the AGILE Study

    Molecular Characterization of Clinical Response and Relapse in Patients with <i>IDH1</i>m ND-AML Treated with Ivo+AZA in the AGILE Study από Hartmut Döhner, Dylan M. Marchione, Sung Choe, Pau Montesinos, Christian Récher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Claudio Cerchione, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Adolfo de la Fuente, Jianan Hui, Prapti Patel, Diego A. Gianolio, Scott R. Daigle, Courtney D. DiNardo, Stéphane de Botton

    Έκδοση 2022
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  16. 16
    Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

    Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study από Huiqiang Huang, Jun Zhu, Ming Yao, Tae Min Kim, Dok Hyun Yoon, Seok‐Goo Cho, Hyeon Seok Eom, Soon Thye Lim, Su-Peng Yeh, Yuqin Song, Yok‐Lam Kwong, Jin Seok Kim, Jie Jin, Yuankai Shi, Hye‐Jin Kim, Qing Min, Tianyuan Zhou, Grace Gao, Zong-qi Dong, Ming Qi, Won Seog Kim

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  17. 17
    A targeted next‐generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice

    A targeted next‐generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice από Po‐Han Lin, Huei‐Ying Li, Sheng‐Chih Fan, Tzu‐Hang Yuan, Ming Chen, Yu‐Hua Hsu, Yu‐Hsuan Yang, Long‐Yuan Li, Su‐Peng Yeh, Li‐Yuan Bai, Yu‐Min Liao, Chen‐Yuan Lin, Ching‐Yun Hsieh, Ching‐Chan Lin, Che‐Hung Lin, Ming‐Yu Lien, Tzu‐Ting Chen, Yen‐Hsuan Ni, Chang‐Fang Chiu

    Έκδοση 2017
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  18. 18
    Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

    Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomiz... από Pau Montesinos, Gail J. Roboz, Claude‐Eric Bulabois, Marion Subklewe, Uwe Platzbecker, Yishai Ofran, Cristina Papayannidis, Agnieszka Wierzbowska, Ho Jin Shin, Vadim Doronin, Stefan Deneberg, Su-Peng Yeh, Mehmet Ali Özcan, Steven Knapper, Jorge E. Cortés, Daniel A. Pollyea, Gert J. Ossenkoppele, Sergio Giralt, Hartmut Döhner, Michael Heuser, Liang Xiu, Indrajeet Singh, Fei Huang, Julie S. Larsen, Andrew H. Wei

    Έκδοση 2020
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  19. 19
    Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

    Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo... από Naveen Pemmaraju, Adam J. Mead, Tim C. P. Somervaille, James McCloskey, Francesca Palandri, Steffen Koschmieder, David Lavie, Brian Leber, Su‐Peng Yeh, María Teresa Gómez‐Casares, Emanuele Ammatuna, Ho‐Jin Shin, Keita Kirito, Éric Jourdan, Timothy Devos, Hun Chuah, Atanas Radinoff, Andrija Bogdanović, Rastislav Moskal, Qi Jiang, Avijeet Chopra, Elektra J. Papadopoulos, Jalaja Potluri, Francesco Passamonti

    Έκδοση 2023
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  20. 20
    Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

    Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia από Keith W. Pratz, Panayiotis Panayiotidis, Christian Récher, Xudong Wei, Brian A. Jonas, Pau Montesinos, Vladimir Ivanov, Andre C. Schuh, Courtney D. DiNardo, Jan Novák, Vlatko Pejša, Don A. Stevens, Su‐Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H. Wei, Cat N. Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler

    Έκδοση 2022
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:

Εργαλεία αναζήτησης: